How an East Bay drug maker pivoted from opioids to the cusp of a seizure drug approval


The company could win FDA approval later this year of a drug it bought in fall 2014.

Previous AbbVie Biotherapeutics director leads team against cancer
Next Developer eyes 168 apartment units in northern Loveland